JumpStarting Drug Review

JumpStarting Drug Review

The Food and Drug Administration’s (FDA) “JumpStart” program is modernizing the review process for new drug approvals. FDA medical reviewers are using “JumpStart’s” automated analytics and data-driven tools to more efficiently assess data from clinical trials, helping to ensure safe and effective drugs are approved for public use. This innovation demonstrates the value that data analytics can play in allowing the FDA to more effectively manage complex drug reviews. The “Jumpstart” approach has the potential for application to other areas subject to FDA review.

In recent years, new drug applications have been growing in size and complexity. Food and Drug Administration (FDA) scientists and clinicians review clinical trial data to assess their safety and effectiveness. Effective data analysis and support has become critical for evaluating and managing drug reviews. To help keep up with the increasing number of complex drugs review, the FDA’s Center for Drug Evaluation and Research’s Office of Computational Science developed “JumpStart.”

The “JumpStart” program packages tools, technologies, and data assessments to provide FDA reviewers with feedback on the quality, composition, and exploratory safety analyses of clinical trial data at the earliest stage possible. Within the first month of the review process, JumpStart provides this important feedback so reviewers better understand the data and have the information necessary to conduct an effective evaluation. JumpStart helps highlight areas that may warrant further attention and clarifies issues before proceeding with a full review. This allows drug reviewers to spend their time on the substantive aspects of drug review, as opposed to data cleaning or assessing whether the data provided is sufficient for review. The “JumpStart” program is one of many ways FDA is working to continue to protect and promote public health.

TEAM MEMBERS
Timothy Kropp, Food and Drug Administration
Lilliam Rosario, Food and Drug Administration
Charles Cooper, BD Worldwide
Helena Sviglin, Food and Drug Administration
Patricia Koussis, Food and Drug Administration
DeYett Law, Food and Drug Administration
John Ho, Food and Drug Administration
Joy Li, Food and Drug Administration
Mary Doi, Food and Drug Administration
Eileen Navarro, Food and Drug Administration
Bobbie Witczak, Food and Drug Administration

READ RELATED BLOG POSTS
HHS IDEA Lab Blog

RELATED WEBSITES
FDA Drug Webpage 

RELATED VIDEOS

This video is undergoing remediation for compliance with Section 508. The anticipated completion date for the remediation is 10/1/2014. If, in the interim, you need any accessibility assistance with this video, please contact Steven Randazzo at steven.randazzo@hhs.gov or by phone at 202-690-6568. 

Share!
Email this to someoneTweet about this on TwitterShare on FacebookShare on LinkedInShare on Google+
A federal government Website managed by the U.S. Department of Health & Human Services
200 Independence Avenue, S.W. - Washington, D.C. 20201